Background: In India, the number of people suffering from Alzheimer's disease (AD) and other dementias is expected to rise every year, owing to continuous growth in the elderly population and consistent increases in life expectancy. Aim: To assess the current state of clinical practise in India, as well as the cost of anti-dementia medications in the Indian context. Methods and Materials: A literature study and data mining of prospective and retrospective studies were used to investigate the pattern of anti-dementia drug use. In India, a cost analysis was conducted to determine the huge range of prices for the same anti-dementia medicine in different formulations. According to prospective and retrospective research, Alzheimer's disease is the most frequent subtype of dementia, and donepezil is still the most widely prescribed medicine. A cost analysis of anti-dementia medications manufactured by a variety of companies in India revealed a wide range of prices between the lowest and highest. Rivastigmine (1.5 mg capsule) had the highest cost-to-benefit ratio, whereas piracetam had the lowest (400 mg tablet). The percent cost variation of all anti-dementia medications was found to be greater than 100. Conclusion: In India, a large range of pricing for the same medicine in several formulations has a significant economic impact. More research is needed to better understand and assess the prescription and use patterns of anti-dementia medications, as they have a significant socioeconomic impact on patients and carers in developing countries such as India.
Author(s)
Details
S.
Ray
CSIR-National Institute of Science Communication and Policy
Research (CSIR-NIScPR), formerly known as CSIR-National Institute of Science
Technology and Development Studies (NISTADS), India.
No comments:
Post a Comment